Project Grant R21AG093042
Award Date 9/1/25
Completion Date 8/31/27
Dollars Obligated $460K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
San Francisco, CA 94143, USA
Similar Awards
- This federal Project Grant award of $461,146.00, provided by the National Institute on Aging (part of the U.S. Department of Health and Human Services) under the Aging Research program (CFDA 93.866), supports research at Yale University aimed at investigating the role of fibroblast growth factor receptor (FGFR) signaling in the pathogenesis of idiopathic pulmonary fibrosis (IPF). The key objectives are to (1) conduct in-vitro studies of FGFR isoform-specific signaling in primary lung cells and...
- The University of Pittsburgh has been awarded a $325,950 project grant from the National Institute on Aging's Aging Research program (CFDA 93.866) to conduct research on preventing pulmonary fibrosis. The research aims to establish that the tyrosine kinase protein FGR, which is induced in senescent lung cells, initiates pulmonary fibrosis by secreting proinflammatory proteins and recruiting inflammatory cells. The project will use mouse models to confirm the role of FGR in pulmonary fibrosis and...
- This federal Project Grant award from the National Institute on Aging (NIA), part of the U.S. Department of Health and Human Services, provides $667,664 to the University of Pittsburgh to study the impacts of air pollution and cigarette smoke on lung aging. The project, running from August 2025 to July 2027, will utilize human organoid and precision cut lung slice models to define how particulate matter (PM2.5) and cigarette smoke exposure influence mitochondrial dysfunction and cellular...
- This $789,664 Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) will support a research project titled "Dissecting the Cellular and Spatial Tissue Clock of the Human Lung and Peripheral Blood" at the Icahn School of Medicine at Mount Sinai. The project aims to leverage single-cell RNA sequencing and spatial transcriptomics to characterize the effect of age on the cellular microenvironment of the human lung and peripheral blood. The research will...
- This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $639,740.00 to investigate the role of the CD38 enzyme in the development of chronic lung conditions following viral infections like COVID-19. The research aims to explore how targeting CD38 on CD8 tissue resident memory (TRM) cells could mitigate age-associated lung fibrosis after viral pneumonia. The award, effective December 15, 2024 through November 30, 2029, will support the lead researcher...
- This Cooperative Agreement award, totaling $943,301.00, was provided by the National Institute on Aging (NIA) under the Aging Research Federal Grant Program (CFDA 93.866) to the University of Southern California (USC). The award funds the pre-clinical development of two novel small molecule therapeutics for the treatment of idiopathic pulmonary fibrosis (IPF), a severe and fatal lung disease. Specifically, the grant supports research and development efforts on: 1) CX-1015, a GP130 small molecule...
- This Project Grant award from the National Heart Lung and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) provides $695,421 to The Regents of the University of California, San Francisco (UCSF) to conduct research on reversing the pathogenic remodeling observed in idiopathic pulmonary fibrosis (IPF). The project aims to define pro-reparative differentiation pathways in both the fibroblast and stem cell compartments that can be leveraged as a therapy. Key objectives include: Tracing...
- This $292,279 federal Project Grant awarded by the National Institute on Aging (CFDA 93.866 - Aging Research) supports Artiam Bio Inc., a small disadvantaged biotechnology company, in validating the APT101 compound for the treatment of systemic sclerosis-associated interstitial lung disease (SSc-ILD) in an aging murine model. The project aims to evaluate the comparative efficacy of APT101 and investigate the mechanistic effects of the compound on endothelial function in the fibrotic lung, with...
- This federal Project Grant award, provided by the National Heart Lung and Blood Institute under the Cardiovascular Diseases Research program (CFDA 93.837), supports research on the role of purinergic signaling in fibroblast activation and lung fibrosis. The $728,577 grant, awarded to the Regents of the University of California, San Francisco, aims to investigate the mechanisms by which the ATP receptor P2RX4 influences fibrotic pathways in lung fibroblasts. The research seeks to elucidate the...
- The federal Project Grant award of $108,978.00 from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) supports research to investigate the mechanisms underlying the age-related decline in the regenerative capacity of alveolar type 2 (AT2) cells in the lung. The principal investigator and research team at the Harvard T.H. Chan School of Public Health will conduct studies to determine whether elevated interferon gamma (IFNG) levels and changes in resident...